Nancy Chang

Dr. Chang is currently serving as the Chairman and CEO of Ansun Biopharma, a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses including SARS-CoV-2. She also serves as CEO and President of Apex Enterprises, Inc., an investment management company focused on investments in healthcare, education and socially responsible ventures. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C. Prior to OrbiMed, Dr. Chang was the Co-Founder, President, Chief Executive Officer and Chairman of Tanox (1986-2006). In 2000, Tanox raised $250M and went public on NASDAQ making it the second largest Biotech IPO in the biotech industry. Tanox was acquired by Genentech for $919 Million in 2007. From 1980-1986, Dr. Chang held several leadership positions at Centocor, Inc., now a division of Johnson and Johnson. During 1986-1992, she was also an Associate Professor at Baylor College of Medicine. Her pharmaceutical development experience stemmed from her tenure at the Roche Institute of Molecular Biology from 1979-1980. During her 30-year tenure in the biotechnology industry, she has developed and commercialized a number of highly successful diagnostic and therapeutic products. Dr. Chang graduated from National Tsing Hua University in Taiwan and received her Ph. D. from the Division of Medical Sciences at Harvard Medical School in 1979.